Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast calculation
1.4 Covid-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Global meningococcal vaccines market 360º synopsis, 2018 – 2032 (USD Million)
2.1.1 Business trends
2.1.2 Region trends
2.1.3 Vaccine type trends
2.1.4 Brand trends
2.1.5 Serotype trends
2.1.6 Age group trends
2.1.7 Distribution channel trends
Chapter 3 Meningococcal Vaccines Market Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of meningitis
3.2.1.2 Increasing government initiatives
3.2.1.3 Mandatory vaccination requirements
3.2.2 Industry pitfalls & challenges
3.2.2.1 Limited supply of the vaccine
3.2.2.2 High costs of vaccine
3.3 Growth potential analysis
3.3.1 By vaccine type
3.3.2 By brand
3.3.3 By serotype
3.3.4 By age group
3.3.5 By distribution channel
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
3.5.1 U.S.
3.5.2 Europe
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players, 2022
4.4 Competitive positioning matrix, 2022
4.5 Strategic dashboard, 2022
Chapter 5 Meningococcal Vaccines Market Estimates and Forecast, By Vaccine Type, 2018 - 2032 (USD Million)
5.1 Key trends, by vaccine type
5.2 Polysaccharide
5.3 Conjugate
5.4 Combination
5.5 Other vaccine types
Chapter 6 Meningococcal Vaccines Market Estimates and Forecast, By Brand, 2018 - 2032 (USD Million)
6.1 Key trends, by brand
6.2 Bexsero
6.3 Nimenrix
6.4 Trumenba
6.5 Menactra
6.6 Menveo
6.7 Other brands
Chapter 7 Meningococcal Vaccines Market Estimates and Forecast, By Serotype, 2018 - 2032 (USD Million)
7.1 Key trends, by serotype
7.2 Serotype A
7.3 Serotype B
7.4 Serotype C
7.5 Serotype W-135
7.6 Serotype Y
Chapter 8 Meningococcal Vaccines Market Estimates and Forecast, By Age Group, 2018 - 2032 (USD Million)
8.1 Key trends, by age group
8.2 Infant (0 to 2 years)
8.3 Children & teen (2 to 18 years)
8.4 Adult (18 years and above)
Chapter 9 Meningococcal Vaccines Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 (USD Million)
9.1 Key trends, by distribution channel
9.2 Hospital pharmacy
9.3 Retail pharmacy
9.4 Online pharmacy
Chapter 10 Meningococcal Vaccines Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)
10.1 Key trends, by region
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East & Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 Rest of Middle East & Africa
Chapter 11 Company Profiles
11.1 Sanofi SA
11.2 GlaxoSmithKline plc
11.3 Pfizer Inc.
11.4 Novartis AG
11.5 Nuron Biotech
11.6 Hualan Biological Engineering Inc.
11.7 Serum Institute of India Ltd.
11.8 JN International Medical Corporation
11.9 Merck & Co., Inc
11.10 Walwax Biotechnology Co., Ltd
